AGTC Applied Genetic Technologies Co

6.20
0  -3%
Previous Close 6.40
Open 6.40
Price To book 0.98
Market Cap 112.11M
Shares 18,083,000
Volume 91,688
Short Ratio 2.57
Av. Daily Volume 170,368

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 ongoing.
AAV Gene Therapy
CNGB3 Achromatopsia
Phase 1/2 data due mid-2017.
rAAV-hRS1
X-linked retinoschisis (XLRS)

Latest News

  1. AGTC to Present at the 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
  2. ETFs with exposure to Applied Genetic Technologies Corp. : April 19, 2017
  3. Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q2, 2017 By the Numbers : March 15, 2017
  4. Perrigo Launches First to Market OTC Equivalent of Rogaine
  5. Applied Genetic Technologies (AGTC) Shares March Higher, Can It Continue?
  6. AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
  7. Tenet Healthcare (THC) to Divest Operations to Amedisys
  8. AGTC Selected as Top Company in the University of Florida’s 2017 Gator100
  9. Applied Genetic Technologies posts 2Q profit
  10. AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2016
  11. AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 8, 2017
  12. AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness
  13. Implied Volatility Surging for Applied Genetic Technologies (AGTC) Stock Options
  14. ETFs with exposure to Applied Genetic Technologies Corp. : December 22, 2016
  15. Applied Genetic Technologies Corp (AGTC): Are Hedge Funds Right About This Stock?
  16. ETFs with exposure to Applied Genetic Technologies Corp. : November 29, 2016
  17. These 5 Stocks Are Ready to Break Out